Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study

Annals of Oncology

Volumn 29, Issue 1, 2018, Pages 154-161

  Han, H S ^a   Dieras V ^b   Robson, M ^c   Palacova M ^d   Marcom, P K ^e   Jager, A ^f   Bondarenko, I ^g   Citrin, D ^h   Campone, M ⁱ   Telli, M L ^j   Domchek, S M ^k   Friedlander, M ^l   Kaufman, B ^m   Garber, J E ⁿ   Shparyk, Y ^o   Chmielowska, E ^p   Jakobsen, E H ^q   Kaklamani, V ^r   Gradishar, W ^s   Ratajczak, C K ^t   Nickner, C ^t   Qin, Q ^t   Qian, J ^t   Shepherd, S P ^t   Isakoff, S J ^u   Puhalla, S ^v   more..

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b INSTITUT CURIE   (France)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Oddéleni nukleární medicíny Regionálni centrum aplikované molekulami onkologie Masaryk v onkologický ústav   (Czech Republic)

^e DUKE UNIVERSITY   (United States)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

^g Dnipropetrovsk State Medical Academy   (Ukraine)

^h Landstuhl Regional Medical Center   (United States)

ⁱ UMR INSERM U892 CNRS 6299   (France)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l PRINCE OF WALES HOSPITAL   (Australia)

^m SHEBA MEDICAL CENTER   (Israel)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

^o Chemotherapy Department   (Ukraine)

^p NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^q LILLEBAELT HOSPITAL   (Denmark)

^r University of Texas Health Science Center at San Antonio   (United States)

^s NORTHWESTERN UNIVERSITY   (United States)

^t ABBVIE INC   (United States)

^u MASSACHUSETTS GENERAL HOSPITAL   (United States)

^v UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

more..

Author keywords

Metastatic breast cancer; PARP inhibitors; Platinum; Temozolomide

Indexed keywords

CARBOPLATIN; PACLITAXEL; PLACEBO; TEMOZOLOMIDE; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE;

ADULT; ADVERSE EVENT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC BREAST CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CLINICAL TRIAL; GENETICS; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SINGLE BLIND PROCEDURE; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARBOPLATIN; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PLACEBOS; SINGLE-BLIND METHOD; TEMOZOLOMIDE; YOUNG ADULT;

EID: 85041174932     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx505     Document Type: Article

References (25)

1. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999; 1: 14-17.
2. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26: 882-893.
3. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
4. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
5. Coleman RL, Sill MW, Bell-McGuinn K et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015; 137: 386-391.
6. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-250.
7. Sandhu SK, Schelman WR, Wilding G et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14: 882-892.
8. Donawho CK, Luo Y, Penning TD et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumormodels. Clin Cancer Res 2007; 13: 2728-2737.
9. Appleman LJ, Beumer JH, Jiang Y et al. A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies. J Clin Oncol 2012; 30(Suppl): abst 3049.
10. Isakoff SJ, Mayer EL, He L et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33: 1902-1909.
11. Tutt A, Ellis P, Kilburn L et al. The TNT trial: a randomized phase III of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). In 37th Annual San Antonio Breast Cancer Symposium, Edition. San Antonio, TX 2014.
12. Isakoff SJ, Overmoyer B, Tung NM et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010; 28: 15(Suppl): 1019.
13. Isakoff SJ, Overmoyer B, Tung NM et al. A phase II trial expansion cohort of the PARP inhibitor veliparib (ABT888) and temozolomide in BRCA1/2 associated metastatic breast cancer. Cancer Res 2011; 71(Suppl 24): abstnr P3-16-05.
14. Trudeau ME, Crump M, Charpentier D et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol 2006; 17: 952-956.
15. Robson M, Im SA, Senkus E et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377: 523-533.
16. Clamp A, Jayson G. PARP inhibitors in BRCA mutation-associated ovarian cancer. Lancet Oncol 2015; 16: 10-12.
17. Molina J, Erlichman C, Northfelt D et al. Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity. Cancer Res 2009; 69(Suppl 9): abst 3602.
18. Puhalla S, Beumer JH, Pahuja S et al. Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). J Clin Oncol 2014; 32(Suppl 15): abst 2570.
19. Murai J, Zhang Y, Morris J et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 2014; 349: 408-416.
20. Maag D, Solomon L, Hopkins T et al. Rationale for the combination of veliparib with platinum-based chemotherapy. J Clin Oncol 2015; 33(Suppl 15): abst 2556.
21. Murai J, Huang SY, Das BB et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588-5599.
22. Hopkins T, Solomon L, Shi Y et al. PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism. Eur J Cancer 2014; 50(Suppl 6): 82-83, abst 246.
23. Dhawan MS, Bartelink IH, Aggarwal RR et al. A phase I study of carboplatin and talazoparib in patients with and without DNA repair mutations. J Clin Oncol 2017; 35(Suppl): abst 2527.
24. Geyer CE, O'Shaughnessy J, Untch M et al. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). J Clin Oncol 2017; 35(Suppl): abst 520.
25. Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors-three and counting. Cancer Discov 2013; 3: 20-23.